Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure

Molecular Cancer Therapeutics

Volumn 6, Issue 6, 2007, Pages 1877-1885

  Robey, Robert W ^a,b   Shukla, Suneet ^a   Steadman, Kenneth ^a   Obrzut, Tomasz ^a   Finley, Elizabeth M ^a   Ambudkar, Suresh V ^a   Bates, Susan E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Building 10 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; 2 [1 (3 DIMETHYLAMINOPROPYL) 5 METHOXY 1H INDOL 3 YL] 3 (1H INDOL 3 YL)MALEIMIDE; 2 BROMO 12,13 DIHYDRO 5H INDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE; 7 HYDROXYSTAUROSPORINE; ADENOSINE TRIPHOSPHATASE; ARCYRIAFLAVIN A; BISINDOLYLMALEIMIDE; BREAST CANCER RESISTANCE PROTEIN; CDK 4I; CEP 701; CYCLIN DEPENDENT KINASE INHIBITOR; ENZASTAURIN; FUMITREMORGIN C; GO 7874; INDOLOCARBAZOLE; K 252A; K 252C; KT 5720; KT 5823; MIDOSTAURIN; PHEOPHORBIDE; PROTEIN KINASE INHIBITOR; QUERCETIN; RUBOXISTAURIN; SB 218078; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HEK293; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG LABELING; DRUG STRUCTURE; EMBRYO; ENZYME ACTIVITY; FLOW CYTOMETRY; FLUORESCENCE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN TRANSPORT; WILD TYPE;

ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CARBAZOLES; CELL LINE; HUMANS; INDOLES; MALEIMIDES; MOLECULAR STRUCTURE; NEOPLASM PROTEINS; PROTEIN KINASE INHIBITORS;

EID: 34250761431     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0811     Document Type: Article

References (48)

1. Cohen P. Protein kinases-the major drug targets ofthe twenty-first century? Nat Rev Drug Discov 2002;1:309-15.
2. Monnerat C, Henriksson R, Le Chevalier T, et al. Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer. Ann Oncol 2004;15:316-23.
3. Eder JPJ, Garcia-Carbonero R, Clark JW, et al. A phase I trial ofdaily oral 4′-N-benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies. Invest New Drugs 2004;22:139-50.
4. Smith BD, Levis M, Beran M, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004;103:3669-76.
5. Querfeld C, Rizvi MA, Kuzel TM, et al. The selective protein kinase Cβ inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J Invest Dermatol 2006;126:1641-7.
6. Graff JR, McNulty AM, Hanna KR, et al. The protein kinase Cβ-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005;65:7462-9.
7. Barry OP, Kazanietz MG. Protein kinase C isozymes, novel phorbol ester receptors and cancer chemotherapy. Curr Pharm Des 2001;7:1725-44.
8. Eastman A, Kohn EA, Brown MK, et al. A novel indolocarbazole, ICP-1, abrogates DNA damage-induced cell cycle arrest and enhances cytotoxicity: similarities and differences to the cell cycle checkpoint abrogator UCN-01. Mol Cancer Ther 2002;1:1067-78.
9. Budworth J, Davies R, Malkhandi J, Gant TW, Ferry DR, Gescher A. Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistant MCF-7/Adr cells. Br J Cancer 1996;73:1063-8.
10. Sedlak J, Hunakova L, Sulikova M, Chorvath B. Protein kinase inhibitor-induced alterations ofdrug uptake, cell cycle and surface antigen expression in human multidrug-resistant (Pgp and MRP) promyelocytic leukemia HL-60 cells. Leuk Res 1997;21:449-58.
11. Beltran PJ, Fan D, Fidler IJ, O'Brian CA. Chemosensitization of cancer cells by the staurosporine derivative CGP 41251 in association with decreased P-glycoprotein phosphorylation. Biochem Pharmacol 1997;53:245-7.
12. Merritt JE, Sullivan JA, Drew L, et al. The bisindolylmaleimide protein kinase C inhibitor, Ro 32-2241, reverses multidrug resistance in KB tumour cells. Cancer Chemother Pharmacol 1999;43:371-8.
13. Gekeler V, Boer R, Ise W, Sanders KH, Schachtele C, Beck J. The specific bisindolylmaleimide PKC-inhibitor GF 109203X efficiently modulates MRP-associated multiple drug resistance. Biochem Biophys Res Commun 1995;206:119-26.
14. Gekeler V, Boer R, Uberall F, et al. Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF 109203X on P-glycoprotein-mediated multidrug resistance. Br J Cancer 1996;74:897-905.
15. Komatani H, Kotani H, Hara Y, et al. Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure. Cancer Res 2001;61:2827-32.
16. Nakagawa R, Hara Y, Arakawa H, Nishimura S, Komatani H. ABCG2 confers resistance to indolocarbazole compounds by ATP-dependent transport. Biochem Biophys Res Commun 2002;299:669-75.
17. Robey RW, Steadman K, Polgar O, et al. Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res 2004;64:1242-6.
18. Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003;22:7340-58.
19. Robey RW, Medina-Perez WY, Nishiyama K, et al. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (MXR/BCRP/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res 2001;7:145-52.
20. Kawabata S, Oka M, Shiozawa K, et al. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem Biophys Res Commun 2001;280:1216-23.
21. Maliepaard M, van Gastelen MA, de Jong LA, et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999;59:4559-63.
22. Schellens JH, Maliepaard M, Scheper RJ, et al. Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications. Ann N Y Acad Sci 2000;922:188-94.
23. Diestra JE, Scheffer GL, Catala I, et al. Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J Pathol 2002;198:213-9.
24. Damiani D, Tiribelli M, Calistri E, et al. The prognostic value of Pglycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype. Haematologica 2006;91:825-8.
25. Uggla B, Stahl E, Wagsater D, et al. BCRP mRNA expression v. clinical outcome in 40 adult AML patients. Leuk Res 2005;29:141-6.
26. Robey RW, Polgar O, Deeken J, To KW, Bates SE. ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev 2007;26:39-57.
27. Zhou S, Schuetz JD, Bunting KD, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety ofste m cells and is a molecular determinant ofth e side-population phenotype. Nat Med 2001;7:1028-34.
28. Scharenberg CW, Harkey MA, Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 2002;99:507-12.
29. Zhang W, Mojsilovic-Petrovic J, Andrade MF, Zhang H, Ball M, Stanimirovic DB. The expression and functional characterization of ABCG2 in brain endothelial cells and vessels. FASEB J 2003;17:2085-7.
30. Kruijtzer CM, Beijnen JH, Rosing H, et al. Increased oral bioavailability of topotec an in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 2002;20:2943-50.
31. Maliepaard M, Scheffer GL, Faneyte IF, et al. Subcellular localization and distribution ofthe breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001;61:3458-64.
32. Fetsch PA, Abati A, Litman T, et al. Localization ofthe ABCG2 mitoxantrone resistance-associated protein in normal tissues. Cancer Lett 2006;235:84-92.
33. Robey RW, Honjo Y, Morisaki K, et al. Mutations at amino acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer 2003;89:1971-8.
34. Ozvegy-Laczka C, Varady G, Koblos G, et al. Function-dependent conformational changes of the ABCG2 multidrug transporter modify its interaction with a monoclonal antibody on the cell surface. J Biol Chem 2005;280:4219-27.
35. Shukla S, Robey RW, Bates SE, Ambudkar SV. The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2. Biochemistry 2006;45:8940-51.
36. Chearwae W, Anuchapreeda S, Nandigama K, Ambudkar SV, Limtrakul P. Biochemical mechanism ofmodulation of human P-glycoprotein (ABCB1) by curcumin I, II, III purified from turmeric powder. Biochem Pharmacol 2004;68:2043-52.
37. Ambudkar SV. Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells. Methods Enzymol 1998;292:504-14.
38. Ozvegy C, Litman T, Szakacs G, et al. Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun 2001;285:111-7.
39. Sanchez-Martinez C, Shih C, Faul MM, et al. Aryl[a]pyrrolo[3,4-c] carbazoles as selective cyclin D1-4 inhibitors. Bioorg Med Chem Lett 2003;13:3835-9.
40. Weisberg E, Boulton C, Kelly LM, et al. Inhibition ofmutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 2002;1:433-43.
41. Millward MJ, House C, Bowtell D, et al. The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study. Br J Cancer 2006;95:829-34.
42. Marshall JL, Kindler H, Deeken J, et al. Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor. Invest New Drugs 2005;23:31-7.
43. Furukawa Y, Vu HA, Akutsu M, et al. Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines. Leukemia 2007;21:1005-14.
44. Benderra Z, Faussat AM, Sayada L, et al. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin Cancer Res 2004;10:7896-902.
45. Wilson CS, Davidson GS, Martin SB, et al. Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood 2006;108:685-96.
46. Legrand O, Simonin G, Beauchamp-Nicoud A, Zittoun R, Marie JP. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. Blood 1999;94:1046-56.
47. Takano M, Yumoto R, Murakami T. Expression and function of efflux drug transporters in the intestine. Pharmacol Ther 2006;109:137-61.
48. Seamon JA, Rugg CA, Emanuel S, et al. Role ofthe ABCG2 drug transporter in the resistance and oral bioavailability ofa potent cyclin-dependent kinase/Aurora kinase inhibitor. Mol Cancer Ther 2006;5:2459-67.